Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Luke Evnin - aVenture Research

Luke Evnin

AddedMar 31, 2024

UpdatedOct 12, 2026

Luke Evnin

Luke Evnin

Co-Founder, MPM Capital

Luke Evnin's Career

DigiTx Partners

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Investment FirmBrisbane, CA, US

Board Member· Board

MPM Capital

Investment FirmBoston, MA, US

Co-Founder

Werewolf Therapeutics

Public$128.2MWatertown, WI, US

Board Member· Board

NeuroTherapeutics Pharma

Public$60.7MChicago, IL, US

Board Member· Board

Amphivena Therapeutics

Series C$135.7MCalifornia, US

Founder

Peptimmune

$92.9MCambridge, MA, US

Board Member· Board

Blade Therapeutics

Series B$51.5MSouth San Francisco, CA, US

Board Member· Board

People Similar to Luke Evnin

Geoffrey SmithFounder · Digitalis Ventures

Leadership at DigiTx Partners

David J. KimBoard Member

Yutaka WatanabeBoard Member

Similar to DigiTx Partners

Digitalis VenturesNew York City, NY, USest. 2016Digitalis VenturesNew York City, NY, US · est. 2016

Digitalis: A venture capital firm investing in innovative solutions for human and animal health.

Investment Firm19

DigitalDx VenturesMenlo Park, CA, USest. 2019DigitalDx VenturesMenlo Park, CA, US · est. 2019

DigitalDx Ventures: A woman-led impact fund using AI for early, accurate diagnosis and affordable healthcare.

Investment Firm48

Ambit Health VenturesNewton, MA, USest. 2021Ambit Health VenturesNewton, MA, US · est. 2021

Healthcare-focused VC, Ambit Health Ventures, invests in early-stage digital health and MedTech innovators.

Investment Firm3

Voxel VenturesFrankfurt, Hesse, DEest. 2019Voxel VenturesFrankfurt, Hesse, DE · est. 2019

Voxel Ventures: A private equity firm investing in early-stage digital health startups.

Investment Firm1

Leadership at MPM Capital

Ansbert GadickeCo-Founder

Similar to MPM Capital

MP Healthcare Venture ManagementBoston, MA, USest. 2006MP Healthcare Venture ManagementBoston, MA, US · est. 2006

MP Healthcare Venture Management: A US-based venture capital firm investing in biotech and healthcare sectors.

Investment Firm7

BioImpact CapitalBoston, MA, USest. 2015BioImpact CapitalBoston, MA, US · est. 2015

BioImpact Capital: Investing in biotech startups to address unmet medical needs.

Investment Firm30

MVM PartnersLondon, Greater London, GBest. 2005MVM PartnersLondon, Greater London, GB · est. 2005

MVM Life Science Partners: A global venture capital firm investing in healthcare and pharmaceutical sectors.

Investment Firm35

Pappas CapitalDurham, NC, USest. 1994Pappas CapitalDurham, NC, US · est. 1994

Pappas Capital: A dedicated life science investor, building innovative companies for 26 years.

Investment Firm31

Leadership at Werewolf Therapeutics

Patrick BaeuerleCo-Founder

K. Dane WittrupBoard Member

Mike ShermanBoard Member

Meeta ChatterjeeBoard Member

Dan HicklinBoard Member

Similar to Werewolf Therapeutics

PanTher TherapeuticsWatertown, MA, USCancer Treatmentest. 2016PanTher TherapeuticsWatertown, MA, US · est. 2016

PanTher Therapeutics: Revolutionizing cancer care with an effective, minimal side-effect treatment platform.

Series A · $21.3M13

Leadership at NeuroTherapeutics Pharma

Corey GoodmanBoard Member

Stephen CollinsBoard Member

Fran HellerBoard Member

Dr Thomas R Beck "Tom"Board Member

Christine E SiuBoard Member

Elaine V. JonesBoard Member

Similar to NeuroTherapeutics Pharma

NeuroPro TherapeuticsYachats, OR, USPharmaceuticalsest. 2014NeuroPro TherapeuticsYachats, OR, US · est. 2014

NeuroPro Therapeutics: Developing pharmaceutical solutions for epilepsy and neurological disorders.

Series A · $5.1M5

Leadership at Amphivena Therapeutics

Curtis RueggBoard Member

Peter Van VlasselaerBoard Member

Dr Frank MuehlenbeckBoard Member

Similar to Amphivena Therapeutics

Iyuda TherapeuticsBethesda, MD, USPharmaceuticalsest. 2014Iyuda TherapeuticsBethesda, MD, US · est. 2014

Iyuda Therapeutics: A Maryland-based medical firm innovating treatments for various immuno diseases.

Pre-Seed · $1.4M50

Advent TherapeuticsLumberville, PA, USTherapiesest. 2014Advent TherapeuticsLumberville, PA, US · est. 2014

Advent Therapeutics: Medical organization in Lumberville, PA, specializing in micro-orphan therapies.

Series A · $3M6

Imvaq TherapeuticsNew York City, NY, USCancer Treatmentest. 2018Imvaq TherapeuticsNew York City, NY, US · est. 2018

Imvaq: A biotech firm innovating immuno-oncologics for global cancer treatment.

Series B · $20M8

Abvc BiopharmaFremont, CA, USBiotechnology, Drugsest. 2002Abvc BiopharmaFremont, CA, US · est. 2002

ABVC BioPharma: A clinical-stage biotech firm specializing in oncology, hematology, and ophthalmology therapies.

Public · $1.8M23

Leadership at Peptimmune

Fredric PriceBoard Member

Dr M James Barrett "Jim"Board Member

Similar to Peptimmune

InimmuneMissoula, MT, USImmunotherapeuticsest. 2016InimmuneMissoula, MT, US · est. 2016

Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.

Series A · $22.6M15

Merganser BiotechNewtown Square, PA, USMedicineest. 2011Merganser BiotechNewtown Square, PA, US · est. 2011

Merganser Biotech Inc., a medicine development company, innovates therapeutic treatments for human diseases.

Series A · $28M30

Setpoint MedicalValencia, CA, USBioelectronic Therapiesest. 2007Setpoint MedicalValencia, CA, US · est. 2007

SetPoint Medical: Innovating bioelectronic therapies for autoimmune diseases.

Series D · $344M175

IpiNovyx BioWest Nyack, NY, USTherapeuticsest. 2021IpiNovyx BioWest Nyack, NY, US · est. 2021

IpiNovyx Bio: Pioneering immunoproteasome therapeutics for autoimmune and inflammatory diseases.

Leadership at Blade Therapeutics

Wendye RobbinsCEO

Mark TimneyBoard Member

Jim ScopaBoard Member

Rana Al-HallaqBoard Member

Harry DietzFounder

Similar to Blade Therapeutics

Pliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124

Window TherapeuticsBoston, MA, USCancer Treatmentest. 2021

Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

$256k4

Imvaq TherapeuticsNew York City, NY, USCancer Treatmentest. 2018Imvaq TherapeuticsNew York City, NY, US · est. 2018

Imvaq: A biotech firm innovating immuno-oncologics for global cancer treatment.

Series B · $20M8

Immune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35

AptinyxEvanston, IL, USPharmaceuticalsest. 2015

AptinyxEvanston, IL, US · est. 2015

Aptinyx Inc., a US-based bio-pharmaceutical company, specializes in developing novel treatments for brain and nervous system disorders.

Public · $273.9M12

NeuroviaSan Francisco, CA, USDrugs, Therapeuticsest. 2013NeuroviaSan Francisco, CA, US · est. 2013

NeuroVia, Inc.: A US-based biopharmaceutical company developing therapies for neurological diseases.

Public · $14M75

NeuropathixDoylestown, PA, USTherapeuticsest. 2010NeuropathixDoylestown, PA, US · est. 2010

Neuropathix: An American biopharmaceutical firm specializing in R&D of pain management therapies.

Mistral TherapeuticsSan Diego, CA, USFibrosis Treatmentsest. 2011

Mistral TherapeuticsSan Diego, CA, US · est. 2011

Mistral Therapeutics: A San Diego-based biotech firm specializing in innovative fibrosis treatments.

Series B · $36.4M6

SphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

BLR BioKenosha, WI, USBiologics, Diagnosticsest. 2013BLR BioKenosha, WI, US · est. 2013

Kenosha-based BLR Bio, a private biotech firm, specializes in orphan and specialty fibrotic diseases.